Gufic Biosciences to Meet Investors at Manthan Conference on Feb 9
Gufic Biosciences Limited will attend the Manthan – Systematix India Annual Flagship Conference on February 09, 2026, in Mumbai. The company will hold one-on-one or group meetings with analysts and institutional investors. Discussions will be limited to publicly disclosed information.
This is a standard disclosure regarding participation in an investor conference. No new price-sensitive information is being shared, and the event is a routine interaction with investors.
The announcement is a routine disclosure about an upcoming investor meeting and does not contain any new financial information or significant business developments that would impact the company's sentiment.
Gufic Biosciences Limited has announced its participation in the Manthan – Systematix India Annual Flagship Conference. The company will engage in a one-on-one or group meeting with analysts and institutional investors in person at Mumbai on February 09, 2026.
The meeting schedule is subject to change based on exigencies from either the investor or the company. Gufic Biosciences has confirmed that discussions will be based on publicly available information, and no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting.
This intimation is provided in compliance with Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.